Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Panzem, Panzem NCD, 2ME2, Panzem Nanocrystal Colloidal Dispersion
2-methoxyestradiol · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Open label, oral administration of 2ME2 |
| Name | Type | Description |
|---|---|---|
| Panzem Nanocrystal Colloidal Dispersion (NCD) | DRUG | Panzem NCD 1,000 mg, four times daily for 28 consecutive days |
| Panzem Nanocrystal Colloidal Dispersion | DRUG | Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing |
| 2-methoxyestradiol | DRUG | 800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg. |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of protected health information. 2. Have histologically-confirmed: * epithelial ovarian cancer or * primary peritoneal carcinomatosis or * fallopian tube cancer. Enrollment of patients with clear cell hist...
Top 20 of 25 competitors
2-methoxyestradiol is an investigational small molecule being studied for the treatment of relapsed multiple myeloma. It is being developed by CASI Pharmaceuticals, Inc. (NASDAQ: CASI) and is currently in Phase 2 clinical development. The drug is intended for patients with relapsed or plateau phase multiple myeloma.
2-methoxyestradiol is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CASI. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with relapsed multiple myeloma.
2-methoxyestradiol is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 study of the drug in patients with relapsed or plateau phase multiple myeloma has been completed.
2-methoxyestradiol has one completed clinical trial, identified as NCT00592579, titled "A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma." This Phase 2 study enrolled 60 participants in the United States and was not randomized or double-blinded.
Yes, 2-methoxyestradiol is also known as Panzem. The Phase 2 clinical trial NCT00592579, which evaluated the drug in patients with relapsed or plateau phase multiple myeloma, used the name Panzem in its title. Both names refer to the same investigational drug.